Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease

Clinical Biochemistry

Volumn 44, Issue 16, 2011, Pages 1320-1324

  García Heredia, Anabel ^a   Marsillach, Judit ^b   Aragonès, Gerard ^a   Guardiola, Marta ^a   Rull, Anna ^a   Beltrán Debón, Raúl ^a   Folch, Alba ^a   Mackness, Bharti ^a   Mackness, Michael ^a   Pedro Botet, Juan ^c   Joven, Jorge ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Antioxidants; Chronic hepatitis; Liver cirrhosis; Paraoxonases

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; PARAOXONASE 3; POLYCLONAL ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; SERUM;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 80054087627     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.08.003     Document Type: Article

References (38)

1. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
2. Rodríguez-Sanabria F., Rull A., Beltrán-Debón R., Aragonès G., Camps J., Mackness B., et al. Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. J Mol Histol 2010, 41:379-386.
3. Deakin S.P., Bioletto S., Bochaton-Piallat M.L., James R.W. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med 2011, 50:102-109.
4. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V.R., Navab M., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001, 76:44444-44449.
5. Camps J., Marsillach J., Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009, 46:83-106.
6. Ferré N., Marsillach J., Camps J., Mackness B., Mackness M., Riu F., et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006, 45:51-59.
7. Marsillach J., Ferré N., Vila M.C., Lligoña A., Mackness B., Mackness M., et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem 2007, 40:645-650.
8. Marsillach J., Aragonès G., Mackness B., Mackness M., Rull A., Beltrán-Debón R., et al. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis 2010, 9:46.
9. 4 induced injury. J Gene Med 2008, 10:94-100.
10. Ustundag B., Bahcecioglu I.H., Sahin K., Duzgun S., Koca S., Gulcu F., et al. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental non-alcoholic steatohepatitis model. Dig Dis Sci 2007, 52:2006-2014.
11. Aragonès G., Guardiola M., Barreda M., Marsillach J., Beltrán-Debón R., Rull A., et al. Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study. J Lipid Res 2011, 52:1055-1061.
12. Bertrán N., Camps J., Fernández-Ballart J., Arija V., Ferré N., Tous M., et al. Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. J Lab Clin Med 2005, 145:41-46.
13. Marsillach J., Mackness B., Mackness M., Riu F., Beltrán R., Joven J., et al. Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 2008, 45:146-157.
14. Ferré N., Camps J., Prats E., Vilella E., Paul A., Figuera L., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48:261-268.
15. Plebani M., Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991, 24:219-239.
16. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histolological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
17. Marsillach J., Aragonès G., Beltrán R., Caballería J., Pedro-Botet J., Morcillo-Suárez C., et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009, 42:91-98.
18. Camps J., Marsillach J., Rull A., Alonso-Villaverde C., Joven J. Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv Exp Med Biol 2010, 660:5-18.
19. Chittury S., Farrell G.C. Ethiopathogenesis of nonalcoholic steatohepatitis. Semin Liv Dis 2001, 21:27-41.
20. Marsillach J., Aragonès G., Mackness B., Mackness M., Rull A., Beltrán-Debón R., et al. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis 2010, 9:46.
21. García-Ruiz I., de la Torre P., Díaz T., Esteban E., Fernández I., Muñoz-Yagüe T., et al. Sp1 and Sp3 transcription factors mediate malondialdehyde-induced collagen α1(I) gene expression in cultured hepatic stellate cells. J Biol Chem 2002, 277:30551-30558.
22. Deakin S., Leviev I., Brulhart-Meynet M.C., James R.W. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant rele for polymorphic position -107, implicating the Sp1 transcription factor. Biochem J 2003, 372:643-649.
23. Ferrari A., Maretto S., Girotto D., Volpin D., Bressan G.M. SREBP contributes to induction of collagen VI transcription by serum starvation. Biochem Biophys Res Commun 2004, 313:600-605.
24. Deakin S., Leviev I., Guernier S., James R.W. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase. A role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003, 23:2083-2089.
25. Bowcock A.M., Crandall J., Daneshvar L., Lee G.M., Young B., Zunzunegui V., et al. Genetic analysis of cystic fibrosis: linkage of DNA and classical markers in multiplex families. Am J Hum Genet 1986, 39:699-706.
26. Buchwald M., Zsiga M., Markiewicz D., Plavsic N., Kennedy D., Zengerling S., et al. Linkage of cystic fibrosis to the pro alpha 2(I) collagen gene, COL1A2, on chromosome 7. Cytogenet Cell Genet 1986, 41:234-239.
27. Mochizuki K., Hayashi N., Hiramatsu N., Katayama K., Kawanishi Y., Kasahara A., et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996, 24:1-7.
28. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assman G., von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161:1-16.
29. Sugano M., Tsuchida K., Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-α-induced apoptosis. Biochem Biophys Res Commun 2000, 272:872-876.
30. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., von Eckardstein A., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001, 276:34480-34485.
31. Matsunaga Y., Iguchi K., Nakajima Y., Koyama I., Miyazaki T., Inoue I., et al. Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem Biophys Res Commun 2001, 287:714-720.
32. Fuhrman B., Gantman A., Aviram M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 2010, 211:61-68.
33. Altenhöfer S., Witte I., Teiber J.F., Wilgenbus P., Pautz A., Li H., et al. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem 2010, 285:24398-24403.
34. Witte I., Altenhöfer S., Wilgenbus P., Amort J., Clement A.M., Pautz A., et al. Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis 2011, 2:e112.
35. Samy W., Hassanian M.A. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol 2011, 12:80-85.
36. Ali E.M., Shehata H.H., Ali-Labib R., Esmail Zahra L.M. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. Clin Biochem 2009, 42:1394-1400.
37. Schulpis K.H., Barzeliotou A., Papadakis M., Rodolakis A., Antsaklis A., Papassotiriou I., et al. Maternal chronic hepatitis B virus is implicated with low neonatal paraoxonase/arylesterase activities. Clin Biochem 2008, 41:282-287.
38. Peng W., Zhang C., Lv H., Zhu J., Zang Y., Pang X., et al. Comparative evaluation of the protective potentials of human paraoxonase 1 and 3 against CCl4-induced liver injury. Toxicol Lett 2010, 193:159-166.